Cover Image

Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies

Abstract

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Table of Contents

Key Topics Covered:

Part I: Colorectal Cancer

  • 5.1. The Scope of this Report
  • 6. Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets)
  • 7. Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs)
  • 8. Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies)
  • 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies)
  • 10. Disclaimer
  • 11. Drug Index
  • 12. Company Index
  • Figures: Includes 6 Figures
  • Tables: Includes 242 Tables
  • Total Number of Pages: 1,056

Part II: Apoptosis

  • 5.1. The Scope of this Report
  • 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets)
  • 7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs)
  • 8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies)
  • 9. Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications)
  • 10. Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators)
  • 12. Drug Index
  • 13. Company Index
  • Figures: Includes 6 Figures
  • Tables: Includes 248 Tables
  • Total Number of Pages: 803

Part III: Antibodies

  • 5.2. The Scope of this Report
  • 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (225 Drug Targets)
  • 7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline? (234 Drug Target Strategies and 441 Drugs)
  • 8. Selecting Cancer Indications for Antibody Therapeutics (69 Different Cancer Indications)
  • 9. Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator (168 Investigators)
  • 11. Drug Index
  • 12. Company Index
  • Figures: Includes 5 Figures
  • Tables: Includes 302 Tables
  • Total Number of Pages: 1289

Featured Companies:

This Report Includes the Following Companies:

  • A&G Pharmaceutical
  • Abbott
  • Abiogen
  • AC Immune
  • Access
  • Active Biotech
  • Adherex
  • Advanced Life Sciences
  • AEgera
  • Aeterna Zentaris
  • Affibody
  • Affimed Therapeutics
  • Aida Pharmaceuticals
  • Alchemia
  • Alethia Biotherapeutics
  • Alexion
  • Allos Therapeutics
  • Alnylam
  • AlphaVax
  • Alseres Pharmaceuticals
  • Ambrilia Biopharma
  • Amgen
  • Anavex Life Sciences
  • Antisense Pharma
  • Antisoma
  • Aphios
  • ApopLogic Pharmaceuticals
  • Apotex
  • Arana Therapeutics
  • Ariad
  • Arno Therapeutics
  • ArQule
  • Array BioPharma
  • Astellas
  • AstraZeneca
  • Attenuon
  • AVEO
  • AVI BioPharma
  • Bayer
  • Betapharma
  • BioAlliance Pharma
  • BioAxone
  • Biocompatibles
  • Biogen Idec
  • BioInvent
  • Bionovo
  • BioNumerik
  • Biosceptre
  • Biotecnol
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Can-Fite BioPharma
  • Cancer Advances
  • Cancer Research Technology
  • Celator Pharmaceuticals
  • Celera
  • Celgene
  • Cell Therapeutics
  • Celldex Therapeutics
  • Cellmid
  • Celsion
  • Celtic Pharma
  • Center of Molecular Immunology
  • Cephalon
  • CG Therapeutics
  • ChemGenex Pharmaceuticals
  • ChemoCentryx
  • Choongwae
  • Circadian Technologies
  • Clavis Pharma
  • Cosmo Pharmaceuticals
  • CuraGen
  • CureTech
  • Curis
  • Cyclacel
  • Cylene Pharmaceuticals
  • Cynvec
  • CytImmune Sciences
  • Cytochroma
  • Cytokinetics
  • Daewoong
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Deciphera Pharmaceuticals
  • Dendreon
  • Dyax
  • Dynavax Technologies
  • EGEN Inc
  • Eisai
  • Elan
  • Eli Lilly
  • Enkam Pharmaceuticals
  • EntreMed
  • Enzon
  • Epeius Biotechnologies
  • EpiCept
  • Etubics
  • Exelixis
  • Facet Biotech
  • FasTrack Pharmaceuticals
  • Five Prime Therapeutics
  • GammaCan
  • Genentech
  • Genmab
  • Genta
  • GenVec
  • Genzyme
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • Gliknik
  • GlycoGenesys
  • Gradalis
  • Green Cross
  • Heidelberg Pharma
  • Hoffmann-La Roche
  • Human Genome Sciences
  • Idera Pharmaceuticals
  • IkerChem
  • ImClone Systems
  • ImmunoCellular Therapeutics
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • Incyte Corporation
  • Infinity Pharmaceuticals
  • Innate Pharma
  • InNexus Biotechnology
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Intradigm
  • Introgen Therapeutics
  • Ipsen
  • ISA Pharmaceuticals
  • Isis Pharmaceuticals
  • ISU ABXIS
  • Ivy Medical Chemicals
  • Jennerex Biotherapeutics
  • Johnson & Johnson
  • Kalypsys
  • Kiadis
  • Kirin Pharma
  • Kyowa Hakko Kirin
  • Labopharm
  • Leo
  • Lorus Therapeutics
  • MacroGenics
  • MAT Biopharma
  • Meda
  • Medarex
  • MediGene
  • MedImmune
  • Medisyn Technologies
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrimack
  • Mersana Therapeutics
  • MethylGene
  • Micromet
  • Mitsubishi Tanabe Pharma
  • MolMed
  • Mologen
  • Nektar Therapeutics
  • NeoPharm
  • Neovacs
  • Nerviano Medical Sciences
  • NicOx
  • NIH
  • Nippon Kayaku
  • Non-industrial source
  • Northwest Biotherapeutics
  • Novartis
  • Novelix
  • Novogen
  • Nycomed Pharma
  • OncoGenex Pharmaceuticals
  • OncoMed
  • Onconova
  • Oncothyreon
  • Oncozyme Pharma
  • Onyvax
  • Orca Therapeutics
  • Orchestra Therapeutics
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • OXiGENE
  • Paladin Labs
  • PanaGin
  • Pepscan Therapeutics
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmaclon
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Pharmexa
  • Pharminox
  • Philogen
  • Pierre Fabre
  • Plexxikon
  • POZEN
  • Prima Biomed
  • Pro-Pharmaceuticals
  • Progenics Pharmaceuticals
  • Protherics
  • Reata Pharmaceuticals
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • Rigel
  • Sanofi-Aventis
  • Santaris Pharma
  • Sareum
  • Scancell
  • Seattle Genetics
  • Semafore Pharmaceuticals
  • Shire
  • Sigma-Tau
  • Simcere Pharmaceuticals
  • Spirogen
  • SRI International
  • SuperGen
  • Supratek Pharma
  • Switch Pharma
  • SynDevRx
  • Synta Pharmaceuticals
  • Taiho
  • Takeda
  • Talon Therapeutics
  • Targa Therapeutics
  • Targepeutics
  • Tau Therapeutics
  • Taxolog
  • Telik
  • Teva
  • Thallion Pharmaceuticals
  • The Genetics Company
  • Therion Biologics
  • ThromboGenics
  • Tigris Pharmaceuticals
  • Titan Pharmaceuticals
  • TopoTarget
  • Tracon Pharmaceuticals
  • Transgene
  • Trion Pharma
  • UCB
  • Vaccinex
  • Vascular Biogenics
  • Vertex Pharmaceuticals
  • Vical
  • Wilex
  • VioQuest
  • VioQuest Pharmaceuticals
  • Viragen
  • Viralytics
  • ViroTarg
  • Wyeth
  • Xerion
  • Xoma
  • Yakult Honsha
  • YM BioSciences
  • ZymoGenetics

Featured Drugs:

A Shortlist of Drugs Included are:

  • 131I-tositumomab
  • 2-methoxyestradiol
  • abagovomab
  • ABT-263
  • adecatumumab
  • AEG-35156
  • aflibercept
  • afutuzumab
  • AGS-1C4D4
  • AGS-PSCA
  • ALD-518
  • alemtuzumab
  • alvocidib
  • ALXN-6000
  • AME-133
  • AMG-479
  • Angiozyme
  • Apomab
  • ARQ-197
  • AS-1411
  • atiprimod dimaleate
  • ATN-224
  • belinostat
  • bevacizumab
  • BIIB-022
  • blinatumomab
  • BMS-663513
  • brentuximab vedotin
  • brivanib alaninate
  • BZL-101
  • canfosfamide hydrochloride
  • capecitabine
  • catumaxomab
  • CBLC-102
  • cediranib
  • cenersen
  • cetuximab
  • cintredekin besudotox
  • cixutumumab
  • CNTO-328
  • CNTO-888
  • combretastatin A-4 prodrug
  • conatumumab
  • CS-1008
  • CT-011
  • daratumumab
  • denosumab
  • DI-17E6
  • doxifluridine
  • dulanermin
  • elotuzumab
  • EMD-273063
  • epratuzumab
  • epratuzumab-Y90
  • ertumaxomab
  • everolimus
  • F-50035
  • farletuzumab
  • figitumumab
  • fresolimumab
  • G-250
  • galiximab
  • GCS-100LE
  • GDC-0449
  • GRN-163L
  • HE-3235
  • I-131-labetuzumab
  • ibritumomab tiuxetan
  • idronoxil
  • IMC-3G3
  • IMGN-901
  • indisulam
  • INGN-241
  • INGN-401
  • inotuzumab ozogamicin
  • interferon gamma
  • intetumumab
  • IPH-2101
  • ipilimumab
  • iratumumab
  • irinotecan bead
  • irinotecan hydrochloride
  • ISIS-23722
  • kahalalide F
  • KW-0761
  • L19-SIP
  • lintuzumab
  • LIP-131I
  • lonaprisan
  • lucatumumab
  • lumiliximab
  • lymphomun
  • mapatumumab
  • matuzumab
  • MCS-110
  • MDX-1106
  • MGCD-0103
  • MGN-1703
  • milatuzumab
  • MKC-1
  • MM-111
  • MORAb-009
  • motexafin gadolinium
  • naptumomab estafenatox
  • natalizumab
  • necitumumab
  • nimotuzumab
  • oblimersen sodium
  • ocrelizumab
  • ofatumumab
  • Onyvax-105
  • oregovomab
  • panitumumab
  • panobinostat
  • PARP inhibitors
  • PAT-SC1
  • patupilone
  • PCI-24781
  • perifosine
  • pertuzumab
  • PF-4856884
  • plitidepsin
  • quarfloxacin
  • raltitrexed
  • ramucirumab
  • regorafenib
  • retaspimycin
  • RG 3638
  • RG-1507
  • Rh-Apo2L
  • rilotumumab
  • rituximab
  • robatumumab
  • sagopilone
  • seliciclib
  • tegafur + uracil
  • tegafur + uracil + leucovorin
  • Tenarad
  • tigapotide triflutate
  • tigatuzumab
  • TLN-232
  • tocilizumab
  • trastuzumab
  • tremelimumab
  • triciribine
  • TRU-016
  • TS-1
  • tucotuzumab celmoleukin
  • veltuzumab
  • volociximab
  • voreloxin
  • VX-944
  • XL-647
  • YS-110
  • yttrium Y 90 clivatuzumab tetraxetan
  • zalutumumab
  • Zemab
Show More
Pricing
Get Notified
Email me when related reports are published